Five-fraction SBRT is “a robust and viable alternative” to conventionally or moderately fractionated radiotherapy for prostate cancer, researchers say.
Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.
Gilead has made the decision to withdraw the accelerated approval of Trodelvy (sacituzumab govitecan) for advanced urothelial cancer in the United States.
Vot-ER is an initiative that allows health care institutions to host nonpartisan conversations with patients about voting and direct them to websites where patients can check their registration, ...
Martin and colleagues’ latest study, published in June 2024 in JAMA Health Forum, finds that the Vot-ER project reaches a younger and more racially and ethnically diverse population, groups that are ...